0PT Stock Overview
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Prothena Corporation plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$50.22 |
| 52 Week High | US$64.54 |
| 52 Week Low | US$21.60 |
| Beta | 0.50 |
| 1 Month Change | -6.24% |
| 3 Month Change | -15.79% |
| 1 Year Change | 65.20% |
| 3 Year Change | 305.00% |
| 5 Year Change | 47.71% |
| Change since IPO | 924.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0PT | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.1% | 2.0% | -0.9% |
| 1Y | 65.2% | 14.1% | -9.6% |
Return vs Industry: 0PT exceeded the German Biotechs industry which returned 13.9% over the past year.
Return vs Market: 0PT exceeded the German Market which returned -8.7% over the past year.
Price Volatility
| 0PT volatility | |
|---|---|
| 0PT Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 5.4% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 0PT is more volatile than 75% of German stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: 0PT's weekly volatility has decreased from 15% to 8% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 82 | Gene Kinney | https://www.prothena.com |
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson’s disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer’s disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer’s disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer’s disease.
Prothena Corporation plc Fundamentals Summary
| 0PT fundamental statistics | |
|---|---|
| Market Cap | €2.65b |
| Earnings (TTM) | -€143.80m |
| Revenue (TTM) | €4.74m |
559.9x
P/S Ratio-18.4x
P/E RatioIs 0PT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0PT income statement (TTM) | |
|---|---|
| Revenue | US$5.15m |
| Cost of Revenue | US$120.75m |
| Gross Profit | -US$115.59m |
| Other Expenses | US$40.88m |
| Earnings | -US$156.48m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.03 |
| Gross Margin | -2,242.82% |
| Net Profit Margin | -3,036.03% |
| Debt/Equity Ratio | 0% |
How did 0PT perform over the long term?
See historical performance and comparison